SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0000950170-23-057119
Filing Date
2023-11-01
Accepted
2023-11-01 07:05:08
Documents
14
Period of Report
2023-11-01
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K eypt-20231101.htm   iXBRL 8-K 45063
2 EX-99.1 eypt-ex99_1.htm EX-99.1 295326
3 GRAPHIC img96707757_0.jpg GRAPHIC 5406
  Complete submission text file 0000950170-23-057119.txt   476274

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT eypt-20231101_pre.xml EX-101.PRE 9457
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT eypt-20231101_lab.xml EX-101.LAB 12806
6 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT eypt-20231101.xsd EX-101.SCH 2475
8 EXTRACTED XBRL INSTANCE DOCUMENT eypt-20231101_htm.xml XML 4523
Mailing Address 480 PLEASANT STREET SUITE B300 WATERTOWN MA 02472
Business Address 480 PLEASANT STREET SUITE B300 WATERTOWN MA 02472 617-926-5000
EyePoint Pharmaceuticals, Inc. (Filer) CIK: 0001314102 (see all company filings)

IRS No.: 262774444 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-51122 | Film No.: 231366523
SIC: 3826 Laboratory Analytical Instruments
Industrial Applications and Services